Category: BiovaxID

Cancer vaccines show promise in Phase 3 trials

July 16, 2009 by srrpenna

Three cancer vaccines -- for prostate cancer, melanoma and lymphoma -- have achieved positive results in so-called Phase 3 clinical trials.

At the annual meeting of the American Society of Clinical Oncology held May 29 to June 2, researchers reported that a vaccine against follicular lymphoma, called BiovaxID, delayed remission after chemotherapy by more than one year, on average.

At the same meeting, other researchers said that a melanoma vaccine caused tumors to shrink in twice as many patients as those receiving a standard FDA-approved therapy.